UPDATE: Lilly shares tumble amid questions regarding weight-loss pill
The Indianapolis-based pharmaceutical giant released its second-quarter earnings Thursday along with data from the latest studies of its weight-loss pill, orforglipron.
Eli Lilly and Co.
Articles
Research on reversing Alzheimer’s reveals lithium as potential key
Seven years of investigation by scientists at Harvard Medical School has revealed that the loss of the metal lithium plays a powerful role in Alzheimer’s disease, a finding that could lead to earlier detection, new treatments and a broader understanding of how the brain ages.
More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects
Seventeen of the complaints also name Eli Lilly and Co. competitor Novo Nordisk Inc. as a defendant and make similar allegations about its GLP-1 drug, Ozempic.
Medicare, Medicaid plans to experiment with covering weight loss drugs
Trump administration officials have offered mixed messages about GLP-1s and whether they should be relied upon for weight loss by obese and overweight Americans.
Lilly’s Mounjaro gets mixed results in extensive study vs. Trulicity
A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results showed enough cardio benefits to eventually encourage investors.
Lilly gets limited European backing for Alzheimer’s drug
Lilly previously secured approval for Kisunla in the U.S., Japan and the U.K.
IBJ names 20 in their Twenties honorees for 2025
The up-and-coming leaders represent business, the arts and culture, philanthropy, government and community service.
Drugmaker telehealth deals risk unnecessary prescribing, Senate probe finds
Partnerships between telehealth companies and pharmaceutical giants Pfizer and Indianapolis-based Eli Lilly and Co. raise concerns about conflicts of interest and inappropriate prescribing, according to a Senate investigation released Thursday.
Prices for obesity drugs fall, but affordability still out of reach for many
The medications still amount to around $500 per month for those without insurance—out of reach for many patients. And even for people with insurance, coverage remains uneven.
Lilly drug saves muscle when added to Wegovy weight-loss shot
The combination offers a potential solution to one of the key problems that’s emerged with popular obesity shots.
Lilly hosts Reddit ‘Ask Me Anything’ Q&A on blockbuster weight-loss drug Zepbound
Questions included whether the Indianapolis-based drugmaker is working to improve insurance coverage for the drug and highlighted users’ concerns about comparisons with Novo Nordisk’s Wegovy.
Lilly acquires cardiovascular genetic medicine company for up to $1.3B
Boston-based Verve Therapeutics is a Nasdaq-traded company focused on genetic medicines for cardiovascular disease.
Lilly says weight loss pill has vast opportunity
The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other conditions because it comes in pill form, not an injection.
Lilly, Purdue Strategic Ventures invest in AI-assisted remote lab platform built for speedier research and development
Persist AI announced a $12 million Series A funding round to support its new Cloud Lab platform, allowing companies to use its lab remotely for research and development.
Reports: Lilly eyes Houston for new $5.9B manufacturing facility
Lilly in February announced plans to add four U.S. manufacturing sites at yet-to-be-determined sites as part of a roughly $27 billion investment.
Lilly seeks to expand pain pipeline with $1B acquisition
SiteOne Therapeutics is developing a non-opioid therapy that targets sodium ion channels in the human body to treat pain and sensory hyperexcitability disorders.
Novo to sell Wegovy at $199 a month as copycat availability ends
On Thursday, pharmacies were supposed to stop making the copies of the medications that had become popular during shortages of the brand-name drugs.
Tobias, Lechleiter families donate $20M for clinical innovation, matched by IU Health
The Tobias-Lechleiter Institute will focus on getting more Hoosiers enrolled in clinical trials and advancing medical research at IU Health and the IU School of Medicine.
Novo Nordisk inks $2.2B deal to develop weight-loss pill to rival Lilly’s orforglipron
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last month.
Lilly’s Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly and Co.’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the medications.